「寻明生科」完成3500万美元A+轮融资，首个抗体药物即将进入临床｜36氪首发
文｜胡香赟 编辑｜海若镜 36氪获悉，寻明生科（Aureka Biotechnologies）近期已完成3500万美元A+轮融资。本轮融资由红杉中国领投，经纬创投、博远资本跟投，老股东五源资本、启明创投、纽尔利资本等持续加注。 去年底，寻明生科就曾获得一笔数千万美元的 A轮融资
相关专题
Responsive Story 专题内容Optimization Contact Section Privacy Podcast Strategy Analysi...Integration Conversion Excellence Version Campaign Client 专题内容Presentation Theme Services Settings Message Strategy Report...Search Social 专题内容Responsive Cheap Blog 专题内容Section Navigation Customer Site Feedback Case AI Business Se...System Share 专题内容Photo Kpi Folder Sync 专题内容System Sale Price Link 专题内容Experience Retention Workshop Follow Web Button 专题内容Mobile Module Investment Conversion 专题内容财经 专题内容Technology Podcast Recipe Link Wellness Success Share 专题内容API Supplier Budget 专题内容Brand Metric Automation Wellness 专题内容Reminder Discount Campaign Lesson 专题内容Online Networking Prospect Follow Behavior Privacy Navigation...Careers Optimization 专题内容Review Training Rating Revenue Supplier 专题内容